Astellas Gene Therapies
NEWS
Astellas Gene Therapies is closing its San Francisco biomanufacturing facility, shifting gene therapy manufacturing to North Carolina, cutting at least 17 employees and affecting dozens more.
With the close of these two funds, Andrew Schwab, managing partner at 5AM Ventures, said the firm has raised more than $2.2 billion to invest in the life sciences industry.
“I hope to thread the needle between pricing responsibly and achieving profitability,” Jarrett said.
A patient treated with Astellas Pharma’s experimental gene therapy for patients with X-linked Myotubular Myopathy (XLMTM) has died after a serious adverse event following treatment.
The company announced it paused the screening and dosing of an investigational gene therapy for patients with XLMTM following a serious adverse event report in a trial participant.
It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.
The agency placed the hold on the Astellas company’s trial after two patients died in the trial.
It was a relatively quiet week for clinical trial news. Here’s a look.
The trial remains on clinical hold and continues to indefinitely delay the company’s plans to seek regulatory approval for the treatment.
JOBS
IN THE PRESS